Skip to content

Clinical trials

Completed Lymphoma, Large-Cell, Anaplastic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, Large-Cell, Anaplastic Status: Completed Clear all

254 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200016
200110
200211
200313
200414
200515
200614
200717
200813
200914
201011
201115
20128
20139
20144
20153
20164
20172
20184
20193
20201
20211
20221

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed254

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)44
Fred Hutchinson Cancer Center16
Memorial Sloan Kettering Cancer Center13
Mayo Clinic9
Case Comprehensive Cancer Center8
Seagen Inc.8
National Institutes of Health Clinical Center (CC)7
Children's Oncology Group6
City of Hope Medical Center6
Roswell Park Cancer Institute6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, Large-Cell, Anaplastic254
Lymphoma, Large B-Cell, Diffuse184
Lymphoma, Mantle-Cell167
Burkitt Lymphoma165
Immunoblastic Lymphadenopathy165
Lymphoma, Follicular165
Lymphoma, Non-Hodgkin160
Hodgkin Disease157
Lymphoma, B-Cell, Marginal Zone155
Precursor Cell Lymphoblastic Leukemia-Lymphoma152

Trials

Showing 26 to 50 of 254. Each trial links to its page on Pharma Observatory.

154 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.